Barclays Initiates Coverage of Cellectis S.A. - Depositary Receipt (CLLS) with Overweight Recommendation

Barclays initiated coverage of Cellectis S.A. depositary receipts (NasdaqGM: CLLS) with an Overweight rating on May 28, 2026. The analyst price forecast implies 110.62% upside, a constructive signal for the biotech name. This is supportive analyst coverage rather than a company-operating update, so the likely market impact is limited but positive.

Analysis

Barclays initiated coverage of Cellectis S.A. depositary receipts (NasdaqGM: CLLS) with an Overweight rating on May 28, 2026. The analyst price forecast implies 110.62% upside, a constructive signal for the biotech name. This is supportive analyst coverage rather than a company-operating update, so the likely market impact is limited but positive.